Bank of America Securities analyst Jason Gerberry maintained a Buy rating on Fractyl Health, Inc. (GUTS – Research Report) today. The company’s shares closed yesterday at $6.10.
According to TipRanks, Gerberry is an analyst with an average return of -0.8% and a 43.86% success rate. Gerberry covers the Healthcare sector, focusing on stocks such as Alkermes, Amphastar Pharmaceuticals, and Galapagos.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Fractyl Health, Inc. with a $18.00 average price target.
The company has a one-year high of $14.50 and a one-year low of $5.75. Currently, Fractyl Health, Inc. has an average volume of 312.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Fractyl Health, Inc. (GUTS) Company Description:
Read More on GUTS:
- Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates
- Fractyl Health’s Revita shows improvement in Type 2 diabetes in German study
- Fractyl Health Presents Clinical Update on Revita® German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D)
- Fractyl Health to Present at BofA Securities 2024 Health Care Conference
- Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024
